Nutt D

PreprintKetamine

Mechanisms of anti-depressant and anti- alcohol effects of ketamine in patients with alcohol use disorder

Mollaahmetoglu M, Krecke J, Oldfield C +7

PreprintMDMA

A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials

Burmester V, Nutt D, Aggett L +5

The therapeutic potential of psychedelic drugs: past, present, and future

Nutt D

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes

Frick A, Blest-Hopley G, Grin M +3

PreprintMDMA

A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials

Burmester V, Nutt D, Aggett L +5

ArticleKetamine

Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.

Agnorelli C, Peill J, Sawicka G +18

ArticleDMT

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

Erritzoe D, Barba T, Benway T +15

A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness.

Alnagger NLN, Cardone P, Martial C +15

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.

Martens MAG, Cunha BG, Erritzoe D +3

Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging

Tolle HM, Luppi AI, Lawn T +4

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.

Pellegrini L, Fineberg NA, O'Connor S +11

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.

Harding R, Singer N, Wall MB +5

PreprintKetamine

Detecting neuroplastic effects induced by ketamine in healthy human subjects: a multimodal approach

Agnorelli C, Peill J, Sawicka G +16

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.

Harding R, Singer N, Wall MB +5

Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.

Agnorelli C, Spriggs M, Godfrey K +8

ArticleDMT

Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT).

Piccinini JI, Sanz Perl Y, Pallavicini C +6

ArticleMDMA

MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.

O'Brien S, Nutt D

Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.

O'Connor S, Godfrey K, Reed S +17

Human brain changes after first psilocybin use

Lyons T, Spriggs M, Kerkelä L +20

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.

Erritzoe D, Barba T, Greenway KT +9

A virtual clinical trial of psychedelics to treat patients with disorders of consciousness

Alnagger NL, Cardone P, Martial C +15

Is it now time to prepare psychiatry for a psychedelic future?

Nutt D, Crome I, Young AH

Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.

Roseman L, Erritzoe D, Nutt D +2

Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action".

Bornemann J, Close JB, Ahmad K +6

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.

Copa D, Erritzoe D, Giribaldi B +3

Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations.

Palmisano VF, Agnorelli C, Fagiolini A +4

PreprintDMT

Transient destabilization of whole brain dynamics induced by DMT

Piccinini JI, Perl YS, Pallavicini C +6

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.

Szigeti B, Weiss B, Rosas FE +3

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.

E-Wen McCulloch D, Liechti ME, Kuypers KP +9

When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.

Jacobs E, Murphy-Beiner A, Rouiller I +2

The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.

Szigeti B, Nutt D, Carhart-Harris R +1

Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins.

Szigeti B, Phillips LD, Nutt D

PreprintDMT

Psychological and physiological effects of extended DMT

Luan LX, Eckernäs E, Ashton M +10

Default Mode Network Modulation by Psychedelics: A Systematic Review.

Gattuso JJ, Perkins D, Ruffell S +11

Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression.

Shukuroglou M, Roseman L, Wall M +3

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial

Baumann S, Carhart-Harris R, Nutt D +2

Effects of classic psychedelic drugs on turbulent signatures in brain dynamics.

Cruzat J, Perl YS, Escrichs A +10

Brain dynamics predictive of response to psilocybin for treatment-resistant depression

Vohryzek J, Cabral J, Lord L +6

Psychedelic Psychiatry

Nutt D

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.

Watts R, Kettner H, Geerts D +9

Neuroimaging in psychedelic drug development: Past, present, and future

Wall M, Harding R, Zafar R +3

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.

Murphy R, Kettner H, Zeifman R +10

Europe PMC2021

Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.

Kuc J, Kettner H, Rosas F +5

ArticleLSD

The entropic tongue: Disorganization of natural language under LSD.

Sanz C, Pallavicini C, Carrillo F +8

Europe PMC2021

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Kuypers KP, Ng L, Erritzoe D +6

Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.

Pallavicini C, Vilas MG, Villarreal M +5

ArticleMDMA

A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy.

Sessa B, Higbed L, Nutt D

Psychedelic drugs-a new era in psychiatry? .

Nutt D

Predicting Responses to Psychedelics: A Prospective Study.

Haijen ECHM, Kaelen M, Roseman L +8

Europe PMC2018

ArticleDMT

DMT Models the Near-Death Experience.

Timmermann C, Roseman L, Williams L +6

Europe PMC2018